Saturday 17 October 2026
Export PIII’s income statement to Excel — free account
P3 Health Partners Inc.
PIII Healthcare Medical Care Facilities
P3 Health Partners Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 2.76% from fiscal 2024. In the quarter to June 2026, revenue grew 8.60%, EPS grew 89.9%, free cash flow fell 272.2% and total debt fell 34.1%, each against the same quarter a year earlier.
4.27
0.13
+3.14%
Follow PIII
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 4 | 2 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 0.07 | (5.31) | 0.16 | (0.79) | (1.27) |
P/S ratio |
— | 0.00 | 0.00 | 22.96 | 0.07 | 0.10 | 0.02 | 0.01 |
Altman Z″-Score (non-manufacturers) |
— | — | (6.36) | (0.45) | (14.17) | (3.51) | (7.35) | (10.32) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | (3.38) | — | — |
P/Operating CF |
— | (1,458.28) | (1,458.28) | (549.32) | (2.42) | (7.83) | (0.57) | (0.44) |
P/B ratio |
— | 61.39 | 61.39 | 53.50 | 13.21 | 0.87 | 0.43 | 0.00 |
Price to Tangible BV |
— | 61.39 | 61.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 | 22.87 | 0.15 | 0.15 | 0.12 | 0.18 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.00 | 0.00 | (219.32) | (1.23) | (2.55) | (1.57) | (2.84) |
EV/FCF |
— | 0.00 | 0.00 | (208.62) | (1.21) | (2.49) | (1.54) | (2.84) |
Quick Ratio |
— | — | 0.95 | 0.97 | 0.41 | 0.54 | 0.34 | 0.22 |
Current Ratio |
— | — | 1.00 | 1.01 | 0.42 | 0.55 | 0.37 | 0.24 |
Net Debt/EBITDA |
— | 0.00 | (0.20) | 0.32 | (0.49) | (0.84) | (0.60) | (1.43) |
Debt/Assets |
0.00% | 0.00% | 42.73% | 3.54% | 11.00% | 12.58% | 23.49% | 41.64% |
Debt/Equity |
— | 0.00 | (0.35) | 0.31 | 16.47 | 0.76 | 2.42 | (1.76) |
Asset Turnover |
— | 0.00 | 9.23 | 0.52 | 0.65 | 1.46 | 1.82 | 2.03 |
Operating CF/Net income |
— | 0.67 | 0.78 | 0.42 | 0.47 | 1.32 | 0.81 | 0.62 |
Capex/Depreciation |
— | (3.64) | (2.87) | (0.32) | 0.00 | (0.02) | 0.00 | 0.00 |
Interest Coverage |
— | (15.60) | (11.29) | (17.61) | (136.87) | (10.51) | (14.46) | (4.91) |
| — | 0.00% | 0.00% | (218.34%) | (193.36%) | (78.08%) | (124.59%) | 373.15% | |
| — | 0.00% | (59.02%) | (12.67%) | (16.67%) | (6.65%) | (16.52%) | (20.55%) | |
ROIC |
— | 0.00% | 0.00% | (54.30%) | (1,163.92%) | (50.09%) | (92.83%) | (182.89%) |
Return on Tangible Assets |
— | 0.00% | (489.65%) | (1,712.80%) | 204.44% | 46.34% | 44.32% | 36.19% |
Average Days of Receivables |
— | 0.00 | 34.03 | 29.82 | 27.68 | 35.01 | 30.46 | 23.97 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 25.59% | 11.18% | 18.73% | 15.47% | 9.92% | 7.59% | 7.35% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.91 | 0.86 | 0.77 | 0.73 | 0.75 |
Share Based Compensation of Revenue |
— | 0.33% | 0.09% | 1.31% | 1.85% | 0.47% | 0.38% | 0.38% |
Graham Net Nets |
— | 0.00 | 0.00 | (0.13) | (9.96) | (4.45) | (16.02) | (59.50) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 219.76 |
Earnings Yield |
— | (1.07%) | (1.07%) | (1.07%) | (1,382.38%) | (49.62%) | (400.00%) | (1,295.13%) |
Free Cash Flow Yield |
— | 0.00% | 0.00% | (0.48%) | (165.83%) | (62.63%) | (342.68%) | (800.56%) |
Revenue per Share |
— | 0.00 | 12.28 | 766.43 | 1,261.99 | 667.29 | 516.69 | 446.34 |
Operating CF per Share |
— | 0.00 | (0.61) | (79.93) | (151.54) | (40.06) | (37.92) | (27.91) |
Capex per Share |
— | 0.00 | (0.07) | (4.10) | (2.69) | (0.96) | 0.00 | 0.02 |
Free Cash Flow per Share |
— | 0.00 | (0.69) | (84.03) | (154.22) | (41.02) | (37.92) | (27.89) |
Cash per Share |
— | — | 1.00 | 169.35 | 22.19 | 21.57 | 15.19 | 7.89 |
Shareholders Equity per Share |
— | 0.00 | (3.26) | 328.95 | 7.04 | 74.89 | 26.15 | (47.49) |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (3.26) | 328.95 | 7.04 | 74.89 | 26.15 | (47.49) |
Free Cash Flow |
— | (29.74) | (27.52) | (69.88) | (128.25) | (77.85) | (110.13) | (91.16) |
Working Capital |
— | — | 0.26 | 1.09 | (140.97) | (133.35) | (312.27) | (412.17) |
Capital Expenditures |
— | (1.45) | (2.93) | (3.41) | (2.23) | (1.83) | — | 0.08 |
Net Current Asset Value |
— | 0.00 | (145.77) | (1,890.70) | (770.02) | (552.82) | (523.34) | (678.79) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.17 | 1.31 | 158.69 | 10.05 | 15.02 | 28.96 |
Cash ROIC |
— | 0.00% | 61.38% | (14.03%) | (106.23%) | (26.72%) | (36.21%) | (63.31%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 13.03 | 15.94 | 12.60 | 12.17 | 13.20 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 6.21 | 6.90 | 6.20 | 5.77 | 4.41 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 62.13 | 71.95 | 60.89 | 65.53 | 74.69 | 88.73 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 48.93 | 65.83 | 100.53 | 123.34 | 110.53 |
Average Payables |
— | — | — | 106.22 | 153.17 | 199.01 | 270.38 | 344.22 |
Average Assets |
— | 0.00 | 53.22 | 1,235.27 | 1,620.34 | 868.77 | 822.19 | 720.03 |
Average Common Equity |
— | — | — | 71.67 | 139.70 | 73.99 | 109.03 | (39.65) |
Columns are period end dates